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Edited by Lukas HuberAbstract FCP1, a phosphatase speciﬁc of the carboxyl-termi-
nal-domain of the large subunit of the RNA polymerase II
(RNAPII), stimulates transcription elongation and it is required
for general transcription and cell viability. To identify novel
interacting proteins of FCP1, we used a human cell line express-
ing an epitope ﬂagged FCP1 and proteins, which formed com-
plexes with FCP1, were identiﬁed by mass spectrometry. We
identiﬁed four proteins: RPB2 subunit of the RNAPII, the nucle-
ar kinase, NDR1, the methyltransferase PRMT5 and the enhan-
cer of rudimentary homologue (ERH) proteins. Intriguingly,
both the PRMT5 and ERH proteins are interacting partners
of the SPT5 elongation factor. Interactions of RPB2, ERH,
NDR1 and PRMT5 with FCP1 were conﬁrmed by co-immuno-
precipitation or in vitro pull-down assays. Interaction between
PRMT5 and FCP1 was further conﬁrmed by co-immunoprecip-
itation of endogenous proteins. We found that FCP1 is a genuine
substrate of PRMT5-methylation both in vivo and in vitro, and
FCP1-associated PRMT5 can methylate histones H4 in vitro.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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II; PRMT51. Introduction
The carboxyl-terminal domain (CTD) of RNA polymerase
II (RNAPII) is essential for transcription and has a funda-
mental role as a critical platform for recruiting and coordi-
nating the actions of proteins involved in mRNA
maturation and export of the mature transcript to the cyto-
plasm [1–3]. The phosphorylation pattern of the CTD under-
goes deﬁned changes during transcription; speciﬁcally, the
phosphorylation of serine 5 occurs between transcription ini-
tiation and promoter clearance and modiﬁcation of serine 2 is
found only when RNAPII is associated with the coding re-
gion of the gene [4]. A number of protein serine kinases
and protein serine phosphatases have been implicated in*Corresponding author. Fax: +39 081 2535000.
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doi:10.1016/j.febslet.2004.12.045CTD modiﬁcation by reversible phosphorylation during the
transition from initiation to elongation [3,5–9]. Among the
CTD phosphatases, FCP1 has been studied most intensively
and dephosphorylation of the CTD of RNAPII by FCP1
has been demonstrated to facilitate recycling of the hyper-
phosphorylated form of RNAPII allowing RNAPII to reen-
ter another round of transcription [10]. FCP1 has been
found to be associated with promoter and coding regions,
suggesting a constant requirement for FCP1 during transcrip-
tion elongation [11]. FCP1 is a phosphoprotein in vivo and
phosphorylation of FCP1 is important for its optimal CTD
phosphatase and transcription elongation activities [12,13].
In addition to its CTD phosphatase activity, FCP1 is in-
volved in transcription regulation as a stochiometric compo-
nent of the elongation complex and is essential for cell
viability in budding and ﬁssion yeast [14,15]. Furthermore,
a partial deﬁciency of human FCP1 has been recently found
associated with the Congenital Cataract facial Dysmorphism
Neuropathy syndrome, an autosomal recessive development
disorder that occurs in the Vlax Roma Gypsies endogamous
group [16].
To elucidate the role of FCP1 in vivo, we reported a bio-
chemical characterization of FCP1 associating factors by using
an epitope-tagged FCP1 stably expressing cell line. We recently
demonstrated that FCP1 aﬃnity puriﬁed extracts contained
RNAPII and we identiﬁed as FCP1 partner the Methylosome
Protein 50 (MEP50) [17], one of the three components of the
methylosome complex [18]. Here, we further characterize other
partners of the FCP1 complexes from the stably expressing
FCP1 cell line. Using mass spectrometry, we identiﬁed the
RPB2 subunit of the RNAPII, the (nuclear Dbf2-related) ser-
ine–threonine kinase, NDR1, the methyltransferase PRMT5
and the enhancer of rudimentary homologue (ERH) proteins.
Intriguingly, either PRMT5 or ERH proteins were recently
identiﬁed as interacting partners of the SPT5 elongation factor
[19]. The PRMT5 is a member of the PRMT family of
methyltransferases able to monomethylate or symmetrically
dimethylate arginine residues [20]. Arginine methylation is a
post-translational modiﬁcation that results in the formation
of asymmetrical and symmetrical mono or dimethylated argi-
nines. Although arginine methylation has been shown to regu-
late protein–protein interactions and signal transduction, very
few proteins since now have been shown to be arginineblished by Elsevier B.V. All rights reserved.
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results demonstrate that the FCP1 complex has histone meth-
yltransferase activity and that the FCP1 protein is found meth-
ylated in vivo and can be substrate of PRMT5 mediated
methylation.2. Materials and methods
2.1. Aﬃnity puriﬁcation and identiﬁcation of FCP1-associated proteins
The HHFCP1 cells, expressing a FLAG-tagged FCP1 protein and
mass spectrometry analysis of aﬃnity puriﬁed FCP1-associated factors
have been recently described [17]. Brieﬂy, HHFCP1 cells were cultured
in DMEM supplemented with 10% fetal bovine serum in the presence
of 0.5 mg/ml of G418. FCP1 complexes were aﬃnity puriﬁed with M2
anti-FLAG agarose-conjugated antibody (Sigma) from nuclear ex-
tracts of 4 · 108 HHFCP1 cells and after extensive washes with
BC100 buﬀer [17] followed by FLAG peptide elution in BC100. The
eluted extracts were TCA precipitated, loaded on 5–20% SDS–PAGE,
gels were stained with colloidal blue staining kit (Invitrogen Life Tech-
nologies) and bands were excised from the gel and destained, then the
samples were reduced and carboxyamidomethylated with 10 mM DTT
and 55 mM iodoacetamide in 0.1 M NH4HCO3 buﬀer, pH 7.5, as pre-
viously described [17]. Brieﬂy, tryptic digestion of the alkylated sam-
ples was performed and the resulting peptide mixtures were directly
analyzed on a reﬂectron Voyager DE PRO MALDI-TOF mass spec-
trometer (Applied Biosystems). Peptide mass values recorded in the
MALDI spectra were used for database search using both the Mascot
and the MS-Fit softwares.
2.2. Plasmids
The FLAG-FCP1 has been previously described [17]. To construct
the ERH and NDR1 expression vectors, the DNA sequences
corresponding to the full-length proteins were ampliﬁed by PCR from
Marathon-Ready HeLa cDNA (Clontech), and subcloned into pCMV-
MYC vector (Clontech) to obtain the Myc-ERH andMyc-NDR1 plas-
mids, respectively. GST-FCP1 (833–961) was constructed by inserting
the FCP1 DNA fragment corresponding to aa 833–961 into the EcoRI
sites of pGEX-4T-3 vector (Amersham Biosciences). The WT plasmid
was mutagenized by PCR to generate GST-FCP1 (833–961) mut, in
which lysine residues substituted arginines at positions 913 and 916.
Details of the plasmids construction are available upon request.
Myc-PRMT5, Myc-PRMT5mut and GST-SPT5 have been described
[22], and they were kindly provided by C. Sardet and H. Handa.
2.3. GST pull-down assays
The GST-RPB2 deletion mutants [23] were kindly provided by J.
Parvin. Bacterial cells were lysed in Binding Buﬀer (20 mM Tris–
HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP40, 1 mM PMSF
and protease inhibitors) and subsequently sonicated and recombinant
proteins were puriﬁed using glutathione-resin (Amersham Pharmacia
Biotec). 2 and 5 micrograms of recombinant proteins were incubated
with 5 ll of rabbit reticulocyte lysate containing S35 labeled FCP1 in
a ﬁnal volume of 1 ml of binding buﬀer. After extensive washing, the
bound proteins were separated on 10% SDS–PAGE followed by auto-
radiography.
2.4. Antibodies, co-immunoprecipitations
The following antibodies were used for the immunological tech-
niques: anti-FCP1 (Santa Cruz Biotechnology, Inc.), anti-PRMT5
(Transduction Laboratories), anti-PRMT1 (Santa Cruz Biotechnol-
ogy, Inc), anti-dimethyl-arginine-symmetric SYM11 (Upstate), anti-
c-Myc (9E10) (Santa Cruz Biotechnology, Inc.) and anti-FLAG M2
Monoclonal Antibody-Peroxidase Conjugate (Sigma). Co-immuno-
precipitation from transiently transfected cells was carried out as de-
scribed [24]. One micrograms of whole cell extracts were used and
protein lysates were prepared in buﬀer A (0.2 mM EDTA, 10 mM
HEPES, 1.5 mM MgCl2, 10 mM KCl, 150 mM NaCl, 0.5% NP-40
and protease inhibitor cocktail, Sigma). For the FCP1 immunoprecip-
itation, 3 lg of antibody or IgG plus 25 ll of pre-equilibrated protein
G-Sepharose 4 Fast Flow (Amersham Biosciences) was used; for anti-
cMyc immunoprecipitation, cell lysates were incubated with 25 ll ofsuspension (anti-c-Myc Agarose Coniugate Sigma). All the interac-
tions were carried out overnight at 4 C. Beads were washed at least
ﬁve times using buﬀer A before loading on SDS–PAGE.
2.5. In vitro methyltransferase assays
Twenty micrograms of FLAG-FCP1 and Myc-PRMT5 DNAs
was transfected by calcium-phosphate, into 150 mm diameter plate
of H1299 cells. Three micrgrams of whole cell extracts was immuno-
precipitated with the anti-FLAG M2-Agarose Aﬃnity Gel or
anti-c-Myc Agarose Coniugate (Sigma), respectively. The immuno-
precipitates were rinsed two times with Methylation buﬀer (50 mM
Tris–HCl, pH 7.5, 1 mM EDTA and 1 mM EGTA) at room temper-
ature, resuspended in 0.04 ml of Methylation buﬀer, and 10 lg of
pooled histones (Sigma) and 2 ll (2.75 lCi) of [H3]Ado-Met were
added. Reactions were carried out at 30 for 30 min, and stopped
by the addition of SDS-sample loading buﬀer. Samples were boiled
for 3 min and loaded onto 15% SDS polyacrylamide gels. The gel
was stained in Coomassie Blue, destained, treated with Intensify,
and analyzed by ﬂuorography. The same assay was used using
as substrates GST-SPT5, GST-FCP1 (833–961) and GST-FCP1
(833–961)mut fusion proteins previously eluted from the beads by
glutathione incubation.3. Results
3.1. Identiﬁcation of proteins that copurify with FCP1
Previous studies have shown that FCP1 interacts biochemi-
cally and genetically with several transcription components,
i.e., RNAPII, Transcription Factor IIF (TFIIF), SPT4/SPT5
[5,15,25,26,27]. To further characterize and identify proteins
that co-purify with FCP1, nuclear extracts from HFFCP1
cells, expressing a FLAG-tagged FCP1, were prepared, and
the epitope-tagged FCP1 was isolated by FLAG-antibody
aﬃnity chromatography. After extensive washing of column,
the remaining proteins were competitively eluted with the
FLAG peptide and separated by SDS–PAGE; discrete visible
bands were excised from the gel and subjected to mass spec-
trometry analysis. In addition to the p50, that was previously
reported as MEP50 [17], here we report the identiﬁcation of
the p130, p70, p60 and p12 proteins (Fig. 1). The p130 protein
was identiﬁed as the RPB2 subunit of RNAPII [23], the p70
protein as the protein arginine methyltransferase PRMT5
[20], the p60 protein as the nuclear serine–threonine kinase
NDR1 [28] and the p12 as a protein designated ERH [29].
3.2. Conﬁrmation of interaction of ERH, NDR1 and RBP2
proteins with FCP1
Previous studies have shown that RNAPII interacts bio-
chemically with the CTD phosphatase FCP1, and an fcp1
mutant allele in yeast genetically interacts with the Rpb2,
the second largest subunit of RNAPII [27]. Accordingly with
the genetic interaction in yeast, we found by mass-spectrom-
etry analysis that the mammalian FCP1 co-puriﬁes with
RPB2. We conﬁrmed the association between FCP1 and
the RPB2 subunit of RNAPII by GST pull-down. In partic-
ular, due to the low expression and/or solubility of RPB2 in
bacteria, we used the already described GST-RPB2 deletions
that cover the entire length of the protein [23]. Considering
diﬀerences of molecular weights, equal molar ratios of
GST-fused proteins were used. As shown in Fig. 2A, FCP1
preferentially interacts with the amino-terminal portion of
the RPB2 protein (amino acids 1–606), albeit a weaker inter-
action with the 877–1177 domain was also observed. From
these results, it appears that FCP1 interacts with the Rpb2
Fig. 1. Analysis of FCPI-associated proteins. Coomassie staining of an SDS–PAGE containing the FLAG-eluates of the indicated cell nuclear
extracts; the three lanes indicated as HFFCP1 were loaded with exactly the same amount of FLAG-eluates in order to obtain suﬃcient amount of
protein to be processed. M indicates molecular weight protein marker. Asterisks indicate the speciﬁc bands of the FCP1 associated proteins. Tryptic
peptide sequences of proteins identiﬁed are included in the tables.
Fig. 2. (A) In vitro-translated FCP1 was incubated with 2 and 5 lg of
GST (lanes 1 and 2), GST-RPB2 1-314 (lanes 3 and 4), GST-RPB2
314-606 (lanes 5 and 6), GST-RPB2 607-877 (lanes 7 and 8) and GST-
RPB2 877-1177 (lanes 9 and 10), respectively. In lane (11), 1/20 of the
input is shown. (B) The association of ERH and NDR1 with FCP1
was analyzed by transient co-transfection of H1299 cells with FLAG-
FCP1 along with Myc-ERH or Myc-NDR1 vectors as indicated.
Whole cell lysates from cotransfected cells were immunoprecipitated
with anti-FLAG antibody and Western blot analysis was performed as
indicated. Asterisk indicates an unspeciﬁc band.
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other subunits of PolII might be involved in FCP1 interac-
tion. Next, we sought to validate the speciﬁcity of FCP1/
ERH and FCP1/NDR1 interactions by co-immunoprecipita-
tion assays. H1299 cells were co-transfected with FLAG-
FCP1 along with Myc-ERH and Myc-NDR1 vectors,
respectively. After transfections, cell nuclear extracts were
immunoprecipitated with a c-Myc antibody and analyzed by
Western blotting with anti-FLAG and anti-c-Myc antibodies.
Co-immunoprecipitation was detected in both co-tranfections(Fig. 2, panel B), and the extent of co-immunoprecipitation
relative to the input varied from 3% to 10%. These results
indicate that speciﬁc interaction between FCP1 and ERH
and NDR1 occurs in transiently transfected cells.
3.3. Histone methylation activity co-puriﬁes with FCP1
The identiﬁcation of arginine methyltransferase PRMT5 in
the FLAG-FCP1 puriﬁcation was of particular interest, as
PRMT5 has been demonstrated to modulate gene expression,
and most importantly interacts and methylates the SPT5 elon-
gation factor [19]. Firstly, PRMT5–FCP1 interaction was val-
idated by co-immunoprecipitation analysis of the endogenous
proteins. 293T cell extracts were immunoprecipitated by using
an FCP1 antibody or IgG as negative control and co-immuno-
precipitated proteins analyzed for the presence of PRMT5 by
Western blot. In addition, we probed the same extracts also
with PRMT1, another member of the PRMT methyltransfer-
ase family. The results, shown in Fig. 3A, left panel, conﬁrmed
the speciﬁc association of FCP1 with PRMT5 but not with
PRMT1. As control of immunoprecipitation, the same ﬁlter
was analyzed by Western blot for the presence of the FCP1
protein (lower panel of Fig. 3A).
Furthermore, H1299 cells were transfected with the Myc-
PRMT5 vector and extracts from the transfected cells were
immunoprecipitated with the c-Myc antibody and analyzed
by Western blotting with the PRMT5 and FCP1 antibodies.
The results in Fig. 3(A, right panel) show that the Myc-
PRMT5 protein associates with the endogenous FCP1.
Because PRMT5 dimethylates arginine of histones, we
sought to determine whether the FCP1–PRMT5 interaction
could result in the recruitment of histone methyltransferase
activity by FCP1. To this end, H1299 cells were transfected
with FLAG-FCP1 and Myc-PRMT5 vectors and nuclear ex-
tracts were immunoprecipitated with FLAG and Myc antibod-
ies conjugated to agarose beads, respectively. As controls, the
empty FLAG vector (Mock) and a PRMT5 point mutant
Fig. 3. (A) Left panel: 293T cell extracts were immunoprecipitated with anti-FCP1 or control immunoglobulin (IgG), as indicated. The lane (–)
represents the whole cell extract not immunoprecipitated. Following immunoprecipitation, Western blot analysis was performed as indicated. Right
panel: H1299 were transiently transfected with the Myc-PRMT5 vector; whole cell extracts were immunoprecipitated with the c-Myc antibody and
analyzed by Western blot with the indicated antibodies. (B) Left panel: H1299 cells were transiently transfected with the Myc-PRMT5 and Myc-
PRMT5mut vectors; whole cell extracts were immunoprecipitated with the c-Myc antibody and the immunoprecipitates used in vitro methylation
assay with pooled histones. In the top panel is reported the result visualized by ﬂuorography, in the middle panel the correspondent Coomassie
staining of SDS–PAGE is shown, in the bottom panel the immunoprecipitated extracts were analyzed by Western blot with the c-Myc antibody.
Right panel: H1299 cells were transiently transfected with Myc-PRMT5 or FLAG-FCP1 vectors and whole cell extracts were immunoprecipitated
with the c-Myc or FLAG-antibodies and the immunoprecipitates were then used in in vitro methylation assay with pooled histones. Ten times more
FLAG-FCP1 immunoprecipitated than MycPRMT5 immunoprecipitated extracts were used in the methylation assay to obtain a similar intensity
ﬂuorography signal.
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activity were used. After extensive washing, the beads suspen-
sions were incubated with a pool of histones in the presence of
[H3]Ado-Met and the reaction products were visualized by
SDS–PAGE and ﬂuorography. As shown in Fig. 3B, incuba-
tion of histones with [H3]Ado-Met plus immunoprecipitates
from the empty vector (Mock) resulted in no transfer of the
radioactive methyl groups. In contrast, incubation of immuno-
precipitates from PRMT5 and FCP1 transfected cells resulted
in transfer of methyl groups from [H3]Ado-Met to histones,
while the PRMT5mut immunoprecipitate resulted in a strong
reduction of the intensities of histone methylation. The immu-
noprecipitated extracts used in the methylation reaction were
analyzed by Western blotting with the c-Myc antibody to show
that equivalent amount of the PRMT5 and PRMT5mut pro-
teins was present in the enzyme assay.
By comparison of the Coomassie staining and the ﬂuorogra-
phy of the same SDS–PAGE, we observed that while histones
H2A, H3 and H4 were methylated by the PRMT5 immunopre-
cipitated complex, histone H4 and at a lesser extent histone
H2A were methylated by the FCP1 complex in these experi-
mental conditions. Overall, the results obtained demonstratedthat FCP1 speciﬁcally binds PRMT5 and it recruits speciﬁc
HMT activity capable to methylate histone H4 in vitro. The
methyltransferase activity observed is likely due to PRMT5
recruitment in the co-immunoprecipitated extracts. However,
we cannot exclude that the diﬀerent pattern of methylation ob-
served on the histones substrate could be due to the involve-
ment of diﬀerent cofactors in the two co-immunoprecipitated
complexes.3.4. FCP1 is a bona ﬁde substrate for PRMT5-mediated
methylation
We next attempted to determine whether FCP1 was a sub-
strate for PRMT5-mediated methylation. By inspection of the
FCP1 protein sequence, we identiﬁed potential sites for
PRMT5 methylation in the arginine residue 913 (motif
GRG) and arginine 916 [motif RG] [30,31]. The region of
FCP1 spanning from aa 833 to 961 was subcloned and the
recombinant GST-FCP1 (833–961) protein tested as PRMT5
substrate in an in vitro methyltransferase assay. As positive
control, the SPT5 protein, which is methylated by PRMT5
[19], was included in this assay. PRMT5 was immunoprecip-
Fig. 4. (A) The methylation target sequences of the FCP1 wild-type
and the point mutant FCP1mut are indicated. H1299 were transiently
transfected with Myc-PRMT5 vector and cell extracts were immuno-
precipitated with anti-c-Myc and then used in in vitro methylation
assay with pooled histones, GST-SPT5, GST-FCP1 (833–961), GST-
FCP1 (833–961)mut and GST, as indicated. In the top panel is
reported the result visualized by ﬂuorography, in the bottom panel the
correspondent Coomassie staining of SDS-PAGE is shown. (B) On the
left is shown the Western blot of 293T whole cell lysates with SYM11
and FCP1 antibodies as indicated. The presence of endogenous
methylated FCP1 were detected following immunoprecipitates of 293T
cell extracts with FCP1 antibody (FCP1) or control immunoglobulin
(IgG) and western blot with SYM11 antibody and FCP1 antibody, as
indicated.
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an in vitro methylation assay with the GST-SPT5 and GST-
FCP1 (833–961) fusion proteins. The results reported in Fig.
4A show that PRMT5 methylates the FCP1 substrate to an
extent similar to that of SPT5. These data strongly suggest
that FCP1, like the SPT5 protein, is bona ﬁde substrate for
PRMT5-directed methylation. Potential site for arginine
methylation by PRMT5 at positions 913 and 916 was mu-tated to lysine in the GST-FCP1 (833–961) construct, Fig.
4A. This construct, GST-FCP1 (833–961) mut, was tested
as substrate of methyltransferase by PRMT5 and the results
demonstrate that lysines substitution at positions 913 and
916 severely impaired methylation of the GST-FCP1 (833–
961). Due to the poor solubility and stability of the full
length GST-FCP1 protein that hampered its use in the in vi-
tro methyltransferase assay, we cannot rule out the possibility
that other potential methylation sites in the remaining FCP1
aa sequence are also subjected to methylation.
In addition, we sought to demonstrate if the endogenous
FCP1 is found as a symmetrically dimethylated protein. To
this end, we immunoprecipitated FCP1 from 293T cells and
the immunoprecipitated FCP1 was analyzed by Western blot
with the SYM11 antibody that speciﬁcally recognized symmet-
rically dimethylated arginine containing peptides.
As shown in Fig. 4B, the SYM11 antibody recognize a spe-
ciﬁc subset of methylated proteins in the 293T cell lysate (left
panel); the same extracts immunoprecipitated with the FCP1
antibody but not with a preimmune serum (IgG) revealed
that FCP1 is found as a symmetrically dimethylated protein
in vivo (right panel).4. Discussion
In this study, we describe the isolation of FCP1-interacting
proteins. Our attempt to isolate the FCP1-associated proteins
from stable cell lines resulted in the identiﬁcation of the nucle-
ar kinase NDR1, the RPB2, second larger subunits of RNA-
PII, the PRMT5, a member of the PRMT family of
methyltransferases and ERH, an evolutionarily highly con-
served nuclear protein.
It has been shown that FCP1 is a phosphoprotein [12,13]
and the phosphorylation status of FCP1 modulated its binding
to RAP74. It has been suggested that casein kinase 2, a pleio-
tropic kinase involved in a number of processes, might repre-
sent the major kinase involved in FCP1 phosphorylation.
The possibility that the NDR1 kinase could be involved in
phosphorylation of the FCP1 protein is currently under inves-
tigation.
Our biochemical identiﬁcation of RPB2, the second-largest
subunit of RNAPII, as an in vivo FCP1-interacting protein
is further supported by genetic studies in yeast. A ‘‘synthetic
lethal’’ phenotype was observed in yeast cells bearing fcp1
mutant combined individually with two mutations of
RPB2, which aﬀect transcription elongation [27]. Our ﬁnd-
ings suggest that FCP1 might be recruited to RNAPII
through docking sites on the RPB2 subunit of RNAPII
and on the RAP74 subunit of TFIIF. Interestingly, struc-
tural studies identiﬁed that the FCP1 catalytic activity may
arise from interactions with both CTD and the RPB4/7 sub-
units of RNAPII [32].
We also report the identiﬁcation of ERH in the FCP1
complex. Interestingly, the ERH has been reported to co-
purify with the SPT5 elongation factor [19], and in Xenopus
it was cloned as an interaction partner of DCoH/PCD, a po-
sitive cofactor of HNF1 [33]. Accordingly with previous re-
port [33], we found that GAL4-ERH represses the
transcription of GAL4-bearing promoter (data not shown).
In contrast, direct recruitment of FCP1 results in activation
688 S. Amente et al. / FEBS Letters 579 (2005) 683–689of GAL4-responsive promoters [24]. It thus appears that two
interacting transcription factors (FCP1 and ERH) function
in an opposite manner when tethered to DNA. Because
transcription elongation is subject to positive and negative
controls, we hypothesize that ERH might function as a
counteracting protein of positive elongation factor, such as
FCP1 and SP5.
The identiﬁcation of PRMT5 within the FCP1-containing
complex was of a particular interest. So far, seven diﬀerent
members of the PRMT family have been characterized.
The type I enzymes, which include PRMT1–4 and PRMT6,
generate both monomethylarginine and asymmetrical dime-
thylarginine residues, while the type II enzymes, which in-
clude PRMT5, generate both monomethylarginine and
symmetrical dimethylarginine residues and such modiﬁca-
tions have been shown to regulate protein–protein interac-
tions [34,35]. PRMT1, PRMT2, and PRMT4/CARM1 have
been found to participate in nuclear receptor transcriptional
activation [34]. The methylation of histones H3 and H4 by
PRMT1 and PRMT4/CARM1 correlates with transcrip-
tional activation, suggesting that they act by modifying
chromatin structure. PMRT5 has been previously shown to
methylate free histones as well as Sm proteins, and it has
been shown that PRMT5 is a component of the methylo-
some complex and mediates the assembly of spliceosomal
snRNPs [18,36].
It is pertinent to note that PMRT5 has been recently
found to be associated with several transcription factors
such as Androgen Receptor, SPT5 and Brg1-based hSWI/
SNF complexes [19,37,38]. Finally, PRMT5 was identiﬁed
as a corepressor of cyclin E1 transcription and its methyl-
transferase activity required for repression [22]. The ﬁnding
that PRMT5 co-puriﬁes with diﬀerent nuclear transcription
factors strongly suggests that PRMT5 could be involved in
several processes (transcription versus splicing and/or trans-
location) forming distinct complexes with diﬀerent proteins
in the cytoplasm and in the nucleus. Despite its numerous
functions, the mechanism by which PRMT5 is recruited to
regulate transcription is largely unknown. Of particular
interest is that two diﬀerent elongation factors, i.e., SPT5
and FCP1, are direct target of PRMT5-mediated
methylation. In both cases, speciﬁc arginine residues
methylated by PRMT5 have been identiﬁed. Notably, using
an unbiased proteomic approach it has recently been shown
that both SPT5 and FCP1 are indeed methylated proteins in
vivo [39]. It is likely that PRMT5-mediated methylation
might aﬀect some FCP1 functional properties. SPT5
methylation has been shown to regulate its interaction with
RNAPII [19]. However, we were unable to detect any
diﬀerence in RNAPII aﬃnity between wild-type FCP1 and
the arginine mutant (data not shown). Thus, the func-
tional consequences of FCP1 methylation remain to be
investigated.
Finally, chromatin immunoprecipitation assays showed
that PRMT5 is directly targeted to promoters and that
PRMT5 recruitment may aﬀect chromatin structure [22,38].
Because FCP1 and PRMT5 directly associate to transcribing
genes [11,22,38], we speculate that FCP1-mediated recruit-
ment of PRMT5 may also induce chromatin remodeling
through histone methylation. Accordingly, we found that
FCP1-associated PRMT5 is able to methylate free histone
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